Categorizing and assessing negative symptoms

@article{Bucci2017CategorizingAA,
  title={Categorizing and assessing negative symptoms},
  author={P Bucci and Silvana Galderisi},
  journal={Current Opinion in Psychiatry},
  year={2017},
  volume={30},
  pages={201–208}
}
Purpose of review To provide a review on studies published in the last year relevant to the categorization and assessment of negative symptoms. Recent findings Recent research supported the validity of the ‘deficit/non-deficit schizophrenia’ categorization. Few studies confirmed the validity of the category ‘persistent negative symptoms’, whereas no recent study explored the validity of the category ‘predominant negative symptoms’. The two-factor structure of the negative dimension is supported… 
EPA guidance on assessment of negative symptoms in schizophrenia
TLDR
This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms.
Assessment of negative symptoms in male and female schizophrenia patients using the Polish version of the Brief Negative Syndrome Scale and Self-evaluation of Negative Symptoms
TLDR
The results indicate the existence of significant gender differences in the assessment of negative symptoms in three subscales of the Brief Negative Symptom Scale.
EPA guidance on treatment of negative symptoms in schizophrenia
TLDR
Recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided and although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotics should be considered.
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale
TLDR
The study demonstrated that BNSS has substantial advantages with respect to PANSS for the identification of the avolition domain and subjects with predominant negative symptoms, and showed an excellent internal consistency, convergent and discriminant validity of BnSS.
The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
TLDR
Cariprazine significantly improved negative symptoms in schizophrenia patients in an open-label, flexible-dose, 16-week, observational study in Latvia.
Elucidating negative symptoms in the daily life of individuals in the early stages of psychosis
TLDR
Overall, altered affective experience, anhedonia, social an Shedonia and asociality seem to play less of a role in the daily life of individuals in the early stages of psychosis than previously assumed.
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
TLDR
Significant improvement versus risperidone on most PANSS Negative Subscale items and across all PANSS-derived factors suggests broad-spectrum efficacy for cariprazine in treating negative symptoms of schizophrenia.
Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia
TLDR
Analysis of differences in neurocognitive functioning and quality of life between deficit and non-deficit patients, and specific predictors of both clinical measures found that DSZ, shorter duration of illness were associated with poorer QOL whereas fewer years of education, lower premorbid intelligence were associatedwith poorer overall neuroc cognitive functioning.
Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
TLDR
In conclusion, blonanserin is useful for long-term treatment of chronic schizophrenic patients when the appropriate management of clinical symptoms and adverse drug reactions are applied and may possibly fit both the current real-world clinical setting and the currently recommended approach to antipsychotics.
Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel
TLDR
It is considered that cariprazine, with its distinct advantages including pharmacokinetics/pharmacodynamics, good efficacy and tolerability, represents a drug of choice in the long-term management of schizophrenia not only for patients with predominant negative symptoms but also for those with positive symptoms.
...
1
2
3
...

References

SHOWING 1-10 OF 89 REFERENCES
Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.
TLDR
The results show that the SNS has good psychometric properties and satisfactory acceptance by patients, and the ability of patients with schizophrenia to accurately report their own experiences is demonstrated.
Psychometric evaluation of the negative syndrome of schizophrenia
TLDR
Current instruments for assessing the negative syndrome of schizophrenia were classified into two categories according to their content validity and assessment approach as first- or second-generation instruments, with the NSA being considered a transitional instrument between the two.
The structure of negative symptoms within schizophrenia: implications for assessment.
TLDR
Findings suggest that this construct is multidimensional with at least 2 factors (involving diminished expression and anhedonia-asociality) and the importance of employing assessments that provide adequate coverage of the broad domain of negative symptoms.
The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia
TLDR
The findings suggest that the association between negative symptoms and SQOL is related primarily to experiential deficits, and highlights the importance of measuring the separate subdomains of negative symptoms as distinct constructs.
Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome
TLDR
Long-term stability and outcome of deficit schizophrenia (DS), in comparison with nondeficit schizophrenia (NDS), were assessed and the factor structure and stability of broadly defined negative symptoms and the ability of the identified factors to predict functional outcome were investigated.
A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale.
TLDR
Comparisons of the Brief Negative Symptom Scale and Clinical Assessment Interview for Negative Symptoms suggest that both scales have good psychometric properties, but that there are important distinctions among the items related to motivation and pleasure.
Impact of primary negative symptoms on functional outcomes in schizophrenia
TLDR
Primary negative symptoms significantly contribute to the functional impairment seen in people with schizophrenia and a better understanding of the etiology and pathobiology of these symptoms is required to guide the search for effective therapeutics that promote functional recovery.
Issues in Selection of Instruments to Measure Negative Symptoms
  • D. Daniel
  • Medicine, Psychology
    Schizophrenia Research
  • 2013
TLDR
Two new measures are field testing and refining, the Clinical Assessment Interview for Negative Symptoms (CAINS) and the Brief Negative Symptom Scale (BNSS), which address the five currently recognized domains of negative symptoms, differentiate appetitive from consummatory aspects of anhedonia and address desire for social relationships.
Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts.
TLDR
A two-factor structure of negative symptoms of schizophrenia supports the DSM-V classification and may be relevant for pathophysiology and treatment of schizophrenia and other psychotic disorders.
Stability of the diagnosis of deficit syndrome in schizophrenia.
TLDR
These results provide evidence for the long-term stability of the deficit syndrome in patients with schizophrenia and the reliability of the deficits/nondeficit categorization when diagnosed by those with appropriate training by using cross-sectional and retrospective data.
...
1
2
3
4
5
...